pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - stækkun Æxli, gelding-Þola - heilsueyðandi lyf - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
sandimmun innrennslisþykkni, lausn 50 mg/ml
novartis healthcare a/s - ciclosporinum inn - innrennslisþykkni, lausn - 50 mg/ml
diovan mixtúra, lausn 3 mg/ml
novartis healthcare a/s - valsartanum inn - mixtúra, lausn - 3 mg/ml
certican tafla 0,75 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg
certican tafla 0,5 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg
certican tafla 0,25 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg
trileptal filmuhúðuð tafla 600 mg
novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 600 mg
trileptal filmuhúðuð tafla 300 mg
novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 300 mg
trileptal filmuhúðuð tafla 150 mg
novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 150 mg
desferal stungulyfs-/innrennslisstofn, lausn 500 mg
novartis healthcare a/s - deferoxaminum mesýlat - stungulyfs-/innrennslisstofn, lausn - 500 mg